Current management of low-grade gliomas.

Détails

Ressource 1Télécharger: 27676279AM.pdf (513.00 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_AA45A63A4CB1
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Current management of low-grade gliomas.
Périodique
Current opinion in neurology
Auteur(s)
Hottinger A.F., Hegi M.E., Baumert B.G.
ISSN
1473-6551 (Electronic)
ISSN-L
1350-7540
Statut éditorial
Publié
Date de publication
12/2016
Peer-reviewed
Oui
Volume
29
Numéro
6
Pages
782-788
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The management of patients suffering from low-grade gliomas (LGGs) remains a challenge in absence of a definite curative therapy. The median survival is highly variable, from 2 years (high-risk disease) to over 15 years (low risk). The aim of this review is to provide a practical step-by-step evaluation of the available treatment options for patients with LGGs.
Next to clinical prognostic markers, both the isocitrate dehydrogenase (IDH) mutation status and the status of 1p/19q codeletion are key prognostic factors for the optimal management of patients with LGG. Two recent randomized phase III clinical trials were performed in LGGs. They first compared the efficacy of radiation versus temozolomide (TMZ) chemotherapy in high-risk LGGs. The second trial compared radiation versus radiation combined with procarbazine, lomustine and vincristine chemotherapy.
Regarding molecular prognostic factors, IDH wild-type LGGs have the worst prognosis, independent of therapy, whereas patients with mutated IDH, codeleted 1p/19q LGGs fared best regarding progression-free survival (PFS). In high-risk LGGs, PFS is similar regardless of whether patients have been treated with radiation or TMZ. In the second trial, patients who were treated with combination radiation and chemotherapy showed significant longer overall survival.

Mots-clé
Antineoplastic Agents, Alkylating/therapeutic use, Brain Neoplasms/diagnosis, Brain Neoplasms/drug therapy, Brain Neoplasms/genetics, Brain Neoplasms/therapy, Combined Modality Therapy, Dacarbazine/analogs & derivatives, Dacarbazine/therapeutic use, Disease-Free Survival, Glioma/diagnosis, Glioma/drug therapy, Glioma/genetics, Glioma/therapy, Humans, Mutation, Prognosis, Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/09/2016 16:51
Dernière modification de la notice
20/08/2019 15:14
Données d'usage